LLY

1,019.18

+2.96%↑

JNJ

230.3

+2.26%↑

ABBV

208.61

+0.24%↑

UNH

401.79

+1.9%↑

AZN

186.75

+0.93%↑

LLY

1,019.18

+2.96%↑

JNJ

230.3

+2.26%↑

ABBV

208.61

+0.24%↑

UNH

401.79

+1.9%↑

AZN

186.75

+0.93%↑

LLY

1,019.18

+2.96%↑

JNJ

230.3

+2.26%↑

ABBV

208.61

+0.24%↑

UNH

401.79

+1.9%↑

AZN

186.75

+0.93%↑

LLY

1,019.18

+2.96%↑

JNJ

230.3

+2.26%↑

ABBV

208.61

+0.24%↑

UNH

401.79

+1.9%↑

AZN

186.75

+0.93%↑

LLY

1,019.18

+2.96%↑

JNJ

230.3

+2.26%↑

ABBV

208.61

+0.24%↑

UNH

401.79

+1.9%↑

AZN

186.75

+0.93%↑

Search

Quidel Corp

Open

11.09 -0.36

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

10.76

Max

11.32

Schlüsselkennzahlen

By Trading Economics

Einkommen

602M

-131M

Verkäufe

24M

724M

Gewinnspanne

-18.062

Angestellte

6,500

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+8.18% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

4. Aug. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-509M

700M

Vorheriger Eröffnungskurs

11.45

Vorheriger Schlusskurs

11.09

Quidel Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Mai 2026, 22:50 UTC

Ergebnisse

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12. Mai 2026, 22:49 UTC

Ergebnisse

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12. Mai 2026, 22:32 UTC

Ergebnisse

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12. Mai 2026, 23:48 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12. Mai 2026, 22:57 UTC

Market Talk
Ergebnisse

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12. Mai 2026, 22:26 UTC

Ergebnisse

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12. Mai 2026, 22:25 UTC

Ergebnisse

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12. Mai 2026, 22:25 UTC

Ergebnisse

Aristocrat Leisure Interim Dividend A$0.50/Security

12. Mai 2026, 22:24 UTC

Ergebnisse

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12. Mai 2026, 22:23 UTC

Ergebnisse

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12. Mai 2026, 22:23 UTC

Ergebnisse

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12. Mai 2026, 22:19 UTC

Ergebnisse

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12. Mai 2026, 22:14 UTC

Ergebnisse

CBA: Business Lending Continued to Grow Above System>CBA.AU

12. Mai 2026, 22:14 UTC

Ergebnisse

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12. Mai 2026, 22:13 UTC

Ergebnisse

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12. Mai 2026, 22:12 UTC

Ergebnisse

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12. Mai 2026, 22:12 UTC

Ergebnisse

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12. Mai 2026, 22:11 UTC

Ergebnisse

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12. Mai 2026, 22:11 UTC

Ergebnisse

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12. Mai 2026, 22:10 UTC

Ergebnisse

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12. Mai 2026, 22:09 UTC

Ergebnisse

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12. Mai 2026, 22:09 UTC

Ergebnisse

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12. Mai 2026, 22:08 UTC

Ergebnisse

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12. Mai 2026, 22:07 UTC

Ergebnisse

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12. Mai 2026, 22:06 UTC

Ergebnisse

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12. Mai 2026, 22:06 UTC

Ergebnisse

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12. Mai 2026, 22:05 UTC

Ergebnisse

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12. Mai 2026, 22:04 UTC

Ergebnisse

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12. Mai 2026, 22:04 UTC

Ergebnisse

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12. Mai 2026, 22:04 UTC

Ergebnisse

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Peer-Vergleich

Kursveränderung

Quidel Corp Prognose

Kursziel

By TipRanks

8.18% Vorteil

12-Monats-Prognose

Durchschnitt 12.03 USD  8.18%

Hoch 13 USD

Tief 11 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Quidel Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

6 ratings

1

Buy

4

Halten

1

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

Betriebsergebnis

$

Über Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat